Designing vaccines based on biology of human dendritic cell subsets

Immunity

Volumn 33, Issue 4, 2010, Pages 464-478

  Palucka, Karolina ^a,b,c   Banchereau, Jacques ^a,c   Mellman, Ira ^d  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROVENGE; TUMOR ANTIGEN; VACCINE;

ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HUMAN; MELANOMA; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DRUG DESIGN; HUMANS; SKIN; STEM CELLS; VACCINES;

EID: 77958454596     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2010.10.007     Document Type: Review

References (144)

1. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., Darnell R.B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 1998, 4:1321-1324.
2. Allan R.S., Smith C.M., Belz G.T., van Lint A.L., Wakim L.M., Heath W.R., Carbone F.R. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003, 301:1925-1928.
3. Alvarez D., Harder G., Fattouh R., Sun J., Goncharova S., Stämpfli M.R., Coyle A.J., Bramson J.L., Jordana M. Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J. Immunol. 2005, 174:1664-1674.
4. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
5. Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 2008, 14:623-628.
6. Arima K., Watanabe N., Hanabuchi S., Chang M., Sun S.C., Liu Y.J. Distinct signal codes generate dendritic cell functional plasticity. Sci. Signal. 2010, 3:ra4.
7. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., Marches F., Banchereau J., Palucka A.K. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 2007, 204:1037-1047.
8. Bachem A., Güttler S., Hartung E., Ebstein F., Schaefer M., Tannert A., Salama A., Movassaghi K., Opitz C., Mages H.W., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 2010, 207:1273-1281.
9. Bedoui S., Whitney P.G., Waithman J., Eidsmo L., Wakim L., Caminschi I., Allan R.S., Wojtasiak M., Shortman K., Carbone F.R., et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 2009, 10:488-495.
10. Birkholz K., Schwenkert M., Kellner C., Gross S., Fey G., Schuler-Thurner B., Schuler G., Schaft N., Dörrie J. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010, 116:2277-2285.
11. Bluestone J.A., Mackay C.R., O'Shea J.J., Stockinger B. The functional plasticity of T cell subsets. Nat. Rev. Immunol. 2009, 9:811-816.
12. Boni A., Cogdill A.P., Dang P., Udayakumar D., Njauw C.N., Sloss C.M., Ferrone C.R., Flaherty K.T., Lawrence D.P., Fisher D.E., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010, 70:5213-5219.
13. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
14. Bozzacco L., Trumpfheller C., Siegal F.P., Mehandru S., Markowitz M., Carrington M., Nussenzweig M.C., Piperno A.G., Steinman R.M. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad. Sci. USA 2007, 104:1289-1294.
15. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
16. Brown G.D. Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 2006, 6:33-43.
17. Brown G.D. Sensing necrosis with Mincle. Nat. Immunol. 2008, 9:1099-1100.
18. Cao W., Rosen D.B., Ito T., Bover L., Bao M., Watanabe G., Yao Z., Zhang L., Lanier L.L., Liu Y.J. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 2006, 203:1399-1405.
19. Celluzzi C.M., Falo L.D. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 1997, 108:716-720.
20. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005, 201:1503-1517.
21. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., Mellman I., Prindiville S.A., Viner J.L., Weiner L.M., Matrisian L.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15:5323-5337.
22. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 2004, 4:336-347.
23. Cheng P., Zhou J., Gabrilovich D. Regulation of dendritic cell differentiation and function by Notch and Wnt pathways. Immunol. Rev. 2010, 234:105-119.
24. + T cells. Immunity 2005, 22:371-383.
25. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., Vu Manh T.P., Baranek T., Storset A.K., Marvel J., et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1283-1292.
26. Darnell R.B. Paraneoplastic syndromes. Current Diagnosis in Neurobiology 1994, 137-141. Mosbey-Year Book, Philadelphia, PA. E. Feldmann (Ed.).
27. Delamarre L., Pack M., Chang H., Mellman I., Trombetta E.S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005, 307:1630-1634.
28. Delamarre L., Couture R., Mellman I., Trombetta E.S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 2006, 203:2049-2055.
29. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., Kawakami-Honda N., Goetsch L., Sawamura T., Bonnefoy J., Jeannin P. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17:353-362.
30. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
31. Di Pucchio T., Chatterjee B., Smed-Sörensen A., Clayton S., Palazzo A., Montes M., Xue Y., Mellman I., Banchereau J., Connolly J.E. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat. Immunol. 2008, 9:551-557.
32. Domínguez P.M., Ardavín C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 2010, 234:90-104.
33. Dougan M., Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 2009, 27:83-117.
34. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111.
35. Dullaers M., Li D., Xue Y., Ni L., Gayet I., Morita R., Ueno H., Palucka K.A., Banchereau J., Oh S. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity 2009, 30:120-129.
36. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., Buck D.W., Schmitz J. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 2000, 165:6037-6046.
37. Figdor C.G., van Kooyk Y., Adema G.J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2002, 2:77-84.
38. Finn O.J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 2003, 3:630-641.
39. Flacher V., Sparber F., Tripp C.H., Romani N., Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: Attempts to harness their properties for immunotherapy. Cancer Immunol. Immunother. 2009, 58:1137-1147.
40. Flornes L.M., Bryceson Y.T., Spurkland A., Lorentzen J.C., Dissen E., Fossum S. Identification of lectin-like receptors expressed by antigen presenting cells and neutrophils and their mapping to a novel gene complex. Immunogenetics 2004, 56:506-517.
41. Fujii S., Shimizu K., Kronenberg M., Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 2002, 3:867-874.
42. Fukaura H., Kent S.C., Pietrusewicz M.J., Khoury S.J., Weiner H.L., Hafler D.A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-b1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 1996, 98:70-77.
43. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
44. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., Moser J.M., Mehta R.S., Drake D.R., Castro E., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 2008, 205:3119-3131.
45. Geijtenbeek T.B., van Vliet S.J., Engering A., 't Hart B.A., van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 2004, 22:33-54.
46. Geissmann F., Gordon S., Hume D.A., Mowat A.M., Randolph G.J. Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 2010, 10:453-460.
47. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
48. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
49. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. HPV Vaccine Study group.
50. Hava D.L., Brigl M., van den Elzen P., Zajonc D.M., Wilson I.A., Brenner M.B. CD1 assembly and the formation of CD1-antigen complexes. Curr. Opin. Immunol. 2005, 17:88-94.
51. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001, 194:769-779.
52. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., Schmidt R., Harris A.L., Old L., Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 2003, 171:5140-5147.
53. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., Provost N., Frohlich M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
54. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
55. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., Kroczek R.A. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
56. Idoyaga J., Cheong C., Suda K., Suda N., Kim J.Y., Lee H., Park C.G., Steinman R.M. Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J. Immunol. 2008, 180:3647-3650.
57. Ito T., Wang Y.H., Duramad O., Hanabuchi S., Perng O.A., Gilliet M., Qin F.X., Liu Y.J. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 2006, 103:13138-13143.
58. Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., Qin X.F., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 2007, 204:105-115.
59. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
60. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
61. Jiang A., Bloom O., Ono S., Cui W., Unternaehrer J., Jiang S., Whitney J.A., Connolly J., Banchereau J., Mellman I. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007, 27:610-624.
62. Joffre O., Nolte M.A., Spörri R., Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 2009, 227:234-247.
63. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., Chen C.J., Dunbar P.R., Wadley R.B., Jeet V., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207:1247-1260.
64. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25:221-242.
65. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
66. Kissenpfennig A., Henri S., Dubois B., Laplace-Builhé C., Perrin P., Romani N., Tripp C.H., Douillard P., Leserman L., Kaiserlian D., et al. Dynamics and function of Langerhans cells in vivo: Dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005, 22:643-654.
67. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
68. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., Ueno H., Banchereau J. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 2009, 70:281-288.
69. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., Agouna-Deciat O., Klucar P., Thompson-Snipes L., Zurawski S., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685-1697.
70. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995, 182:459-465.
71. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
72. Leslie D.S., Vincent M.S., Spada F.M., Das H., Sugita M., Morita C.T., Brenner M.B. CD1-mediated γ/δ T cell maturation of dendritic cells. J. Exp. Med. 2002, 196:1575-1584.
73. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169.
74. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24:99-146.
75. Liu Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
76. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007, 23:675-699.
77. Lucas M., Schachterle W., Oberle K., Aichele P., Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
78. + T cells. J. Immunol. 1995, 154:5071-5079.
79. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 1999, 189:587-592.
80. Manicassamy S., Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 2009, 21:185-193.
81. Manicassamy S., Ravindran R., Deng J., Oluoch H., Denning T.L., Kasturi S.P., Rosenthal K.M., Evavold B.D., Pulendran B. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med. 2009, 15:401-409.
82. Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., Pulendran B. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010, 329:849-853.
83. Matsui T., Connolly J.E., Michnevitz M., Chaussabel D., Yu C.I., Glaser C., Tindle S., Pypaert M., Freitas H., Piqueras B., et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 2009, 182:6815-6823.
84. McCurley N., Mellman I. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PLoS ONE 2010, 5:e11949.
85. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
86. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 2008, 8:935-947.
87. Mestas J., Hughes C.C.W. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
88. Mohamadzadeh M., Berard F., Essert G., Chalouni C., Pulendran B., Davoust J., Bridges G., Palucka A.K., Banchereau J. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 2001, 194:1013-1020.
89. Mohamadzadeh M., Duong T., Hoover T., Klaenhammer T.R. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev. Vaccines 2008, 7:163-174.
90. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
91. Mora J.R., Bono M.R., Manjunath N., Weninger W., Cavanagh L.L., Rosemblatt M., Von Andrian U.H. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003, 424:88-93.
92. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
93. Münz C., Steinman R.M., Fujii S. Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 2005, 202:203-207.
94. Nagorsen D., Scheibenbogen C., Marincola F.M., Letsch A., Keilholz U. Natural T cell immunity against cancer. Clin. Cancer Res. 2003, 9:4296-4303.
95. Paczesny S., Banchereau J., Wittkowski K.M., Saracino G., Fay J., Palucka A.K. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J. Exp. Med. 2004, 199:1503-1511.
96. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.P., Johnston D.A., Fay J., Banchereau J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 2006, 29:545-557.
97. Palucka A.K., Ueno H., Fay J.W., Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 2007, 220:129-150.
98. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 1998, 64:358-367.
99. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998, 10:588-594.
100. Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: Immunobiology and use in clinical trials. J. Immunol. 2007, 178:1975-1979.
101. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725.
102. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
103. Pialoux G., Gahéry-Ségard H., Sermet S., Poncelet H., Fournier S., Gérard L., Tartar A., Gras-Masse H., Levy J.P., Guillet J.G. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001, 15:1239-1249. ANRS VAC 04 Study Team.
104. Pilon-Thomas S., Mackay A., Vohra N., Mulé J.J. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 2010, 184:3442-3449.
105. Poulin L.F., Salio M., Griessinger E., Anjos-Afonso F., Craciun L., Chen J.L., Keller A.M., Joffre O., Zelenay S., Nye E., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1261-1271.
106. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203:413-424.
107. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., Pirani A., Gernert K., Deng J., Marzolf B., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009, 10:116-125.
108. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., Blasberg R., Yagita H., Muranski P., Antony P.A., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207:637-650.
109. Reis e Sousa C. Dendritic cells in a mature age. Nat. Rev. Immunol. 2006, 6:476-483.
110. Romani N., Gruner S., Brang D., Kämpgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P.O., Steinman R.M., Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994, 180:83-93.
111. Roncarolo M.G., Bacchetta R., Bordignon C., Narula S., Levings M.K. Type 1 T regulatory cells. Immunol. Rev. 2001, 182:68-79.
112. Roncarolo M.G., Levings M.K., Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 2001, 193:F5-F9.
113. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009, 21:233-240.
114. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
115. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10:490-500.
116. Sancho D., Mourão-Sá D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., Carlyle J.R., Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 2008, 118:2098-2110.
117. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martínez D., Hernanz-Falcón P., Rosewell I., Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
118. Schmitt N., Morita R., Bourdery L., Bentebibel S.E., Zurawski S.M., Banchereau J., Ueno H. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009, 31:158-169.
119. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
120. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
121. Shaw J., Wang Y.H., Ito T., Arima K., Liu Y.J. Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. Blood 2010, 115:3051-3057.
122. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
123. Shortman K., Heath W.R. The CD8+ dendritic cell subset. Immunol. Rev. 2010, 234:18-31.
124. Siddiqui K.R., Laffont S., Powrie F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity 2010, 32:557-567.
125. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
126. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., Godfrey D.I. NKT cells-Conductors of tumor immunity?. Curr. Opin. Immunol. 2002, 14:165-171.
127. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
128. Stoitzner P., Tripp C.H., Eberhart A., Price K.M., Jung J.Y., Bursch L., Ronchese F., Romani N. Langerhans cells cross-present antigen derived from skin. Proc. Natl. Acad. Sci. USA 2006, 103:7783-7788.
129. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
130. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
131. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 2000, 1:515-520.
132. Townsend A.R., Gotch F.M., Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985, 42:457-467.
133. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 2005, 23:975-1028.
134. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., Di Pucchio T., Connolly J., Fay J.W., Pascual V., et al. Dendritic cell subsets in health and disease. Immunol. Rev. 2007, 219:118-142.
135. Ueno H., Schmitt N., Klechevsky E., Pedroza-Gonzalez A., Matsui T., Zurawski G., Oh S., Fay J., Pascual V., Banchereau J., Palucka K. Harnessing human dendritic cell subsets for medicine. Immunol. Rev. 2010, 234:199-212.
136. Valladeau J., Saeland S. Cutaneous dendritic cells. Semin. Immunol. 2005, 17:273-283.
137. van der Aar A.M., Sylva-Steenland R.M., Bos J.D., Kapsenberg M.L., de Jong E.C., Teunissen M.B. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol. 2007, 178:1986-1990.
138. Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., Liu Y.J. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
139. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25:821-852.
140. Welters M.J., Kenter G.G., de Vos van Steenwijk P.J., Löwik M.J., Berends-van der Meer D.M., Essahsah F., Stynenbosch L.F., Vloon A.P., Ramwadhdoebe T.H., Piersma S.J., et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 2010, 107:11895-11899.
141. Wykes M., Pombo A., Jenkins C., MacPherson G.G. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 1998, 161:1313-1319.
142. Yamazaki S., Inaba K., Tarbell K.V., Steinman R.M. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 2006, 212:314-329.
143. Yewdell J.W. Designing CD8+ T cell vaccines: It's not rocket science (yet). Curr. Opin. Immunol. 2010, 22:402-410.
144. Zapata-Gonzalez F., Rueda F., Petriz J., Domingo P., Villarroya F., de Madariaga A., Domingo J.C. 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: Inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J. Immunol. 2007, 178:6130-6139.